Tandem Diabetes Care (NASDAQ: TNDM) experienced a significant stock increase of over 32% on Friday due to strong fourth-quarter results, driven by robust demand for its insulin pumps and an improved gross margin. The company’s new pay-as-you-go pharmacy structure is contributing to margin expansion and recurring revenue. Tandem Diabetes Care anticipates continued profitable growth in 2026, with projected full-year sales between $1.065 billion and $1.085 billion.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Tandem Diabetes Care Stock Popped Today
Tandem Diabetes Care (NASDAQ: TNDM) experienced a significant stock increase of over 32% on Friday due to strong fourth-quarter results, driven by robust demand for its insulin pumps and an improved gross margin. The company’s new pay-as-you-go pharmacy structure is contributing to margin expansion and recurring revenue. Tandem Diabetes Care anticipates continued profitable growth in 2026, with projected full-year sales between $1.065 billion and $1.085 billion.